| Literature DB >> 26327334 |
Malgorzata Klauzinska1, Daniel Bertolette1, Sudhamsh Tippireddy1, Luigi Strizzi2, Peter C Gray3, Monica Gonzales4, Meg Duroux5, Menotti Ruvo6,7, Christian Wechselberger8, Nadia P Castro1, Maria Cristina Rangel1, Annalia Focà7,9, Annamaria Sandomenico6, Mary J C Hendrix10, David Salomon1, Frank Cuttitta1.
Abstract
Cripto-1 (CR-1) is a multifunctional embryonic protein that is re-expressed during inflammation, wound repair, and malignant transformation. CR-1 can function either as a tethered co-receptor or shed as a free ligand underpinning its flexible role in cell physiology. CR-1 has been shown to mediate cell growth, migration, invasion, and induce epithelial to mesenchymal transition (EMT). The main signaling pathways mediating CR-1 effects include Nodal-dependent (Smad2/3) and Nodal-independent (Src/p44/42/Akt) signaling transduction pathways. In addition, there are several naturally occurring binding partner proteins (BPPs) for CR-1 that can either agonize or antagonize its bioactivity. We will review the collective role of CR-1 as an extracellular protein, discuss caveats to consider in developing a quantitation assay, define possible mechanistic avenues applicable for drug discovery, and report on our experimental approaches to overcome these problematic issues.Entities:
Keywords: Autoantibodies; Cripto-1; Cripto-1 detection; drug discovery; inflammation
Mesh:
Substances:
Year: 2015 PMID: 26327334 DOI: 10.3109/03008207.2015.1077239
Source DB: PubMed Journal: Connect Tissue Res ISSN: 0300-8207 Impact factor: 3.417